Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has entered into a definitive securities purchase agreement with healthcare …
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that its Phase 2 “window of opportunity” clinical study of its lead …
Analyst Swayampakula Ramakanth of H.C.
Advaxis, Inc. (NASDAQ:ADXS) and Amgen (NASDAQ:AMGN) announced a global agreement for the development and commercialization of Advaxis’ ADXS-NEO, a novel, preclinical investigational cancer immunotherapy …
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced its combination study of axalimogene filolisbac (AXAL) with AstraZeneca’s anti-PD-L1 durvalumab …
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the U.
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that its lead Lm immunotherapy candidate, axalimogene filolisbac (AXAL), has been …
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced Ranya Dajani joined Advaxis as Vice President, Corporate Development from Bristol-Myers …
In a research report published on Thursday, FBR analyst Vernon Bernardino reiterated an Outperform rating on shares of Advaxis, Inc. (NASDAQ:ADXS) with a price …
Advaxis, Inc. In a research report released today, H.